Registration No. 333-
As
filed with the Securities and Exchange Commission on September 29, 2023
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
F-3
REGISTRATION
STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
ALTERITY
THERAPEUTICS LIMITED
(Exact
name of registrant as specified in its charter)
Australia |
|
Not
Applicable |
(State
or other jurisdiction of |
|
(I.R.S.
Employer |
incorporation
or organization) |
|
Identification
No.) |
ABN
37 080 699 065
Level
14, 350 Collins Street, Melbourne, Victoria 3000 Australia
Tel.
+61-3-9349-4906
(Address
and telephone number of registrant’s principal executive offices)
Puglisi
& Associates
850
Library Avenue, Suite 204
P.O.
Box 885
Newark,
Delaware 19715
Tel.
(302) 738-6680
(Name,
address and telephone number of agent for service)
Copies
of all communications, including communications sent to agent for service, should be sent to:
David
Rodda, Esq.
QR
Lawyers Pty Ltd.
PO
Box 16109, Collins Street West, Vic 8007, Australia
Tel:
(61 3) 8692 9000
Fax:
(61 3) 8692 9040 |
|
Steven
J. Glusband, Esq.
Guy
Ben-Ami, Esq.
Carter
Ledyard & Milburn LLP
28
Liberty Street
New
York, NY 10005
Tel:
212-238-8605
Fax:
212-732-3232 |
Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this Registration
Statement.
If
the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check
the following box. ☐
If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the
following box. ☒
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check
the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. ☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If
this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective
upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐
If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional
securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.
☐
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.
Emerging
growth company ☐
If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided
pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
†
The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards
Board to its Accounting Standards Codification after April 5, 2012.
The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date
as the Commission, acting pursuant to said Section 8(a), may determine.
The
information contained in this prospectus is not complete and may be changed. We may not sell these securities until the registration
statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and
it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.
Subject
to Completion, Dated September 29, 2023
ALTERITY
THERAPEUTICS LIMITED
$50,000,000
Ordinary Shares represented by American Depositary Shares
Warrants
Units
We
may offer to the public from time to time in one or more series or issuances:
| ● | American
depositary shares, or ADSs, with each ADS representing six hundred ordinary shares; or |
|
● |
warrants
to purchase ADSs; or |
|
● |
a
combination of the above as units. |
We
refer to the ordinary shares, ADSs, warrants and units collectively as “securities” in this prospectus.
The
ADSs, are listed on the NASDAQ Capital Market under the symbol “ATHE.” On September 27, 2023, the closing price of an ADS
representing ordinary shares of Alterity Therapeutics Limited on the NASDAQ Capital Market was US$2.51.
The
securities will have a total public offering price not to exceed $50,000,000. This prospectus provides a general description of the securities
we may offer. Each time we sell securities, we will provide specific terms of the securities offered in a supplement to this prospectus.
The prospectus supplement may also add, update, or change information contained in this prospectus. This prospectus may not be used to
consummate a sale of securities unless accompanied by the applicable prospectus supplement. You should read both this prospectus and
any prospectus supplement together with additional information described under the heading “Where You Can Find More Information”
and the documents incorporated or deemed to be incorporated by reference carefully before you make your investment decision.
We
will sell these securities directly to our shareholders or to purchasers or through agents on our behalf or through underwriters or dealers
as designated from time to time. If any agents or underwriters are involved in the sale of any of these securities, the applicable prospectus
supplement will provide the names of the agents or underwriters and any applicable fees, commissions, or discounts. The prospectus supplement
for each offering of securities will describe in detail the plan of distribution for that offering. For general information about the
distribution of securities offered, please see “Plan of Distribution” in this prospectus on page 7.
The
aggregate market value of our outstanding Ordinary Shares held by non-affiliates on 21 September 2023, as calculated in accordance with
General Instruction I.B.5. of Form F-3, was approximately $3.96 million. During the prior 12 calendar month period that ends on, and
includes, the date of this prospectus, we have offered securities with an aggregate market value of approximately $0.12 million pursuant
to General Instruction I.B.5 of Form F-3. Pursuant to General Instruction I.B.5, in no event will we sell securities pursuant to this
prospectus with a value of more than one-third of the aggregate market value of our Ordinary Shares held by non-affiliates in any 12-month
period, so long as the aggregate market value of our Ordinary Shares held by non-affiliates is less than $75,000,000.
INVESTING
IN OUR SECURITIES INVOLVES A HIGH DEGREE OF RISK. SEE “RISK FACTORS” BEGINNING ON PAGE 2 AND UNDER SIMILAR HEADINGS IN THE
OTHER DOCUMENTS THAT ARE INCORPORATED BY REFERENCE INTO THIS PROSPECTUS FOR A DISCUSSION OF CERTAIN FACTORS THAT SHOULD BE CONSIDERED
BY PROSPECTIVE PURCHASERS OF THE SECURITIES OFFERED HEREBY.
NEITHER
THE U.S. SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED
UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
The
date of this prospectus is
TABLE
OF CONTENTS
You
should rely only on the information contained or incorporated by reference in this prospectus. We have not authorized any other person
to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on
it. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume
that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business,
financial condition, results of operation and prospects may have changed since that date.
In
this prospectus, the terms “we,” “us,” “Alterity and “our” mean Alterity Therapeutics Limited
and its subsidiaries, unless otherwise indicated
All
references to “U.S. dollars” or “US$” in this prospectus are to U.S. dollars, and all references to “Australian
dollars” or “A$” are to the currency of Australia.
SUMMARY
This
prospectus is part of a registration statement on Form F-3 that we filed with the Securities and Exchange Commission, or SEC, using a
“shelf” registration process. Under this process, we may sell from time to time any combination of the securities described
in this prospectus in one or more offerings up to a total U.S. dollar amount of $50,000,000 or the equivalent denominated in foreign
currencies or foreign currency units. This prospectus does not contain all of the information included in the registration statement.
For a more complete understanding of the offering of the securities, you should refer to the registration statement, including its exhibits.
This
prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide a prospectus
supplement that will contain specific information about the terms of that offering. The prospectus supplement may also add, update or
change information contained in this prospectus, and may also contain information about any material federal income tax considerations
relating to the securities covered by the prospectus supplement. You should read both this prospectus and any prospectus supplement together
with additional information under the headings “Where You Can Find More Information” and “Incorporation of
Certain Information by Reference.”
This
summary may not contain all of the information that may be important to you. You should read this entire prospectus, including the financial
data and related notes incorporated by reference in this prospectus, before making an investment decision. This summary contains forward-looking
statements that involve risks and uncertainties. Our actual results may differ significantly from the results discussed in the forward-looking
statements. Factors that might cause or contribute to such differences include those discussed in “Risk Factors” and “Forward-Looking
Statements.”
Alterity
Therapeutics Limited
We
were incorporated under the laws of the Commonwealth of Australia on November 11, 1997 and began limited operations shortly thereafter.
Our mission is to develop therapeutic drugs designed to treat neurodegenerative diseases, currently focusing on Parkinsonian and other
movement disorders.
Corporate
Information
Our
registered office is located at Level 3, 62 Lygon Street, Carlton, Victoria 3053 Australia and our telephone number is 011-61-3-9824-5254.
Our principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia and our telephone number
is 011-61-3-9349-4906. Our address on the internet is www.alteritytherapeutics.com. The information in our website is not incorporated
by reference into this prospectus and should not be considered as part of this prospectus.
RISK
FACTORS
Investing
in our securities involves significant risks. Before making an investment decision, you should carefully consider the risks described
under “Risk Factors” in the applicable prospectus supplement and under Item 3.D. – “Risk Factors” in our
most recent Annual Report on Form 20-F, or any updates in our Reports on Form 6-K, together with all of the other information appearing
in this prospectus or incorporated by reference into this prospectus and any applicable prospectus supplement, in light of your particular
investment objectives and financial circumstances. The risks so described are not the only risks facing us. Additional risks not presently
known to us or that we currently deem immaterial may also impair our business operations. Our business, financial condition and results
of operations could be materially adversely affected by any of these risks. The trading price of our securities could decline due to
any of these risks, and you may lose all or part of your investment. The discussion of risks includes or refers to forward-looking statements;
you should read the explanation of the qualifications and limitations on such forward-looking statements discussed elsewhere in this
prospectus.
FORWARD-LOOKING
STATEMENTS
Some
of the statements contained in this prospectus and the documents incorporated by reference are forward-looking statements. Forward-looking
statements involve risks and uncertainties, such as statements about our plans, objectives, expectations, assumptions or future events.
In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “estimate,” “plan,”
“project,” “continuing,” “ongoing,” “expect,” “we believe,” “we intend,”
“may,” “should,” “will,” “could” and similar expressions denoting uncertainty or an action
that may, will or is expected to occur in the future. These statements involve estimates, assumptions, known and unknown risks, uncertainties
and other factors that could cause actual results to differ materially from any future results, performances or achievements expressed
or implied by the forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements about:
| ● | statements
of expected future economic performance; |
| ● | the
future impact of pandemics on the economy and our operations; |
| ● | product
and technology development and rapid technological change; |
| ● | the
potential attributes and benefit of our products and their competitive position; |
| ● | our
estimates regarding expenses, future revenues, capital requirements and our need for additional financing; |
| ● | statements
of our plans and objectives; |
| ● | statements
regarding the capabilities of our business operations; |
| ● | statements
regarding competition in our market; and |
| ● | assumptions
underlying statements regarding us or our business. |
Forward-looking
statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations
and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy
and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks
and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial
condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these
forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those
indicated in the forward-looking statements include, among others, the following:
Risks
Related to Our Financial Condition
| ● | We
have a history of operating losses and our management has concluded that factors raise substantial
doubt about our ability to continue as a going concern and our auditor has included an explanatory
paragraph relating to our ability to continue as a going concern in its audit report for
the fiscal year ended June 30, 2023. |
| ● | We
will need additional funding to complete our clinical trials and to operate our business;
such funding may not be available or, if it is available, such financing is likely to substantially
dilute our existing shareholders. |
Risks
Related to Our Business
| ● | We
are a development stage company engaged in the development of pharmaceutical products and
our success is uncertain. |
| ● | We
rely on research institutions to conduct our clinical trials and we may not be able to secure
and maintain research institutions to conduct our future trials. The institutions that we
work with have their own limits and procedures that will influence or limit our ability to
conduct research and development and the conduct of clinical trials. |
| ● | We
are faced with uncertainties related to our research. |
| ● | Clinical
trials as they relate to our business are expensive and time consuming and their outcome
is uncertain. |
| ● | We
may experience delays in our clinical trials that could adversely affect our business and
operations. |
| ● | We
may not be able to complete the development of our products candidates or develop other pharmaceutical
products. |
| ● | We
may need to prioritise the development of our most promising candidates at the expense of
the development of other products. |
| ● | Our
research and development efforts will be seriously jeopardised if we are unable to retain
key personnel and cultivate key academic and scientific collaborations. |
| ● | If
we are unable to successfully keep pace with technological change or with the advances of
our competitors, our technology and products may become obsolete or non-competitive. |
| ● | Acceptance
of our products in the marketplace is uncertain and failure to achieve market acceptance
will negatively impact our business and operations. |
| ● | We
have limited large scale manufacturing experience with our product candidates. Delays in
manufacturing sufficient quantities of such materials to the required standards for pre-clinical
and clinical trials may negatively impact our business and operations. |
| ● | The
failure to establish sales, marketing and distribution capability would materially impair
our ability to successfully market and sell our pharmaceutical products. |
| ● | If
healthcare insurers and other organisations do not pay for our products, or impose limits
on reimbursement, our future business may suffer. |
| ● | We
may be exposed to product liability claims, which could harm our business. |
| ● | Breaches
of network or information technology security, natural disasters or terrorist attacks could
have an adverse effect on our business. |
Risks
Related to Government Regulation
| ● | If
we do not obtain the necessary governmental approvals, we will be unable to develop or commercialise
our pharmaceutical products. |
| ● | We
will not be able to commercialise any current or future product candidates if we fail to
adequately demonstrate their safety and efficacy. |
| ● | Positive
results in previous clinical trials of product candidates may not be replicated in future
clinical trials, which could result in development delays or a failure to obtain marketing
approval. |
| ● | Even
if approved, any product candidates that we or our subsidiaries may develop and market may
be later withdrawn from the market or subject to promotional limitations. |
| ● | Healthcare
reform measures and other statutory or regulatory changes could adversely affect our business |
| ● | We
could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act. |
Risks
Related to Intellectual Property
| ● | Our
success depends upon our ability to protect our intellectual property and our proprietary
technology, to operate without infringing the proprietary rights of third parties and to
obtain marketing exclusivity for our products and technologies. |
| ● | We
may face difficulties in certain jurisdictions in protecting our intellectual property rights,
which may diminish the value of our intellectual property rights in those jurisdictions. |
| ● | Intellectual
property rights do not address all potential threats to our competitive advantage. |
| ● | Changes
in patent laws or patent jurisprudence could diminish the value of our patents, thereby impairing
our ability to protect our products or product candidates. |
| ● | Confidentiality
agreements with employees and others may not adequately prevent disclosure of our trade secrets
and protect our other proprietary information. |
Risks
Related to Our Compliance with the Sarbanes-Oxley Act of 2002
| ● | We
may fail to maintain effective internal control over financial reporting in accordance with
Section 404 of the Sarbanes-Oxley Act of 2002, which could adversely affect our operating
results, investor confidence in our reported financial information, and the market price
of our ordinary shares and ADSs. |
| ● | Material
weaknesses in our disclosure controls and procedures could negatively affect shareholder
and customer confidence. |
Risks
Related to Ownership of Our Securities
| ● | Our
stock price may be volatile and the trading markets for our securities is limited. |
| ● | Ownership
interest in our company may be further diluted as a result of additional financings. |
| ● | There
is a substantial risk that we are a passive foreign investment company, or PFIC, to some
U.S. investors which will subject those investors to adverse tax rules |
| ● | We
do not anticipate paying dividends on our ordinary shares. |
| ● | Currency
fluctuations may adversely affect the price of our securities. |
| ● | If
we fail to maintain compliance with NASDAQ’s continued listing requirements, our shares
may be delisted from the NASDAQ Capital Market. |
Risks
Related to Our Location in Australia
| ● | It
may be difficult to enforce a judgment in the United States against us and our officers and
directors or to assert U.S. securities laws claims in Australia or serve process on our officers
and directors. |
| ● | As
a foreign private issuer whose shares are listed on The NASDAQ Capital Market, we may follow
certain home country corporate governance practices instead of certain NASDAQ requirements. |
| ● | We
currently do not have a majority of independent directors serving on our Board of Directors,
which may afford less protection to our shareholders than if our Board of Directors had a
majority of independent directors. |
| ● | Australian
takeovers laws may discourage takeover offers being made for us or may discourage the acquisition
of large numbers of our ordinary shares. |
| ● | Our
Constitution and other Australian laws and regulations applicable to us may adversely affect
our ability to take actions that could be beneficial to our shareholders. |
OFFER
STATISTICS AND EXPECTED TIMETABLE
We
may sell from time to time pursuant to this prospectus (as may be detailed in prospectus supplements) an indeterminate number of securities
as shall have a maximum aggregate offering price of $50,000,000. The actual per share price of the securities that we will
offer pursuant hereto will depend on a number of factors that may be relevant as of the time of offer (see “Plan of Distribution”
below).
CAPITALIZATION
The
table below sets forth our capitalization as of June 30, 2023.
| |
As of June 30, 2023 | |
| |
(In A$, except number of shares) | |
Ordinary Shares, no par value, 2,439,897,618 shares issued and outstanding (1) | |
| |
Issued capital | |
| 213,971,323 | |
Reserves | |
| 3,972,475 | |
Accumulated deficit | |
| (195,130,889 | ) |
Total shareholders’ equity | |
| 22,812,909 | |
| (1) | The
number of shares issued and outstanding excludes 844,737,659 ordinary shares issuable upon the exercise of 844,737,659 options, having
exercise prices ranging from $A0.02 to $A0.09 per ordinary share having a weighted average exercise price of $A0.[ ] per ordinary share. |
MARKET
FOR OUR ORDINARY SHARES
Our
ordinary shares have traded on the ASX since our initial public offering on March 29, 2000. Since September 5, 2002 our ADRs have traded
on the NASDAQ Capital Market and since April 8, 2019, when we changed our name to Alterity Therapeutics Limited, under the symbol “ATHE.”
USE
OF PROCEEDS
Except
as otherwise provided in the applicable prospectus supplement, we intend to use the net proceeds from the sale of the securities covered
by this prospectus for ongoing and future clinical trials and research programs into the development of our proprietary compounds, including
our compound ATH434 for Parkinsonian disorders, and for working capital purposes. Additional information on the use of net proceeds
from the sale of securities covered by this prospectus may be set forth in the prospectus supplement relating to the specific offering.
PLAN
OF DISTRIBUTION
We
may sell securities in any of the ways described below, including any combination thereof:
| ● | to
or through underwriters or dealers; |
| ● | through
one or more agents; or |
| ● | directly
to one or more purchasers. |
The
distribution of the securities may be effected from time to time in one or more transactions:
| ● | at
a fixed price, or prices, which may be changed from time to time; |
| ● | at
market prices prevailing at the time of sale; |
| ● | at
prices related to such prevailing market prices; or |
Each
prospectus supplement will describe the method of distribution of the securities and any applicable restrictions. The prospectus supplement
with respect to the securities of a particular series will describe the terms of the offering of the securities, including the following:
| ● | the
name or names of any underwriters, dealers or agents, and the amounts of securities underwritten or purchased by each of them; |
| ● | the
initial public offering price of the securities and the proceeds to us and any discounts, commissions, or concessions allowed or reallowed
or paid to dealers; and |
| ● | any
securities exchanges on which the securities may be listed. |
Any
public offering price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time. In no
event will any underwriter or dealer receive fees, commissions, and markups which, in the aggregate, would exceed 8% of the price of
the shares being registered.
Only
the agents or underwriters named in the prospectus supplement are agents or underwriters in connection with the securities being offered.
We
may authorize underwriters, dealers, or other persons acting as our agents to solicit offers by certain institutions to purchase securities
from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in the prospectus supplement. Each
contract will be for an amount not less than, and the aggregate amount of securities sold pursuant to such contracts shall not be less
nor more than, the respective amounts stated in the prospectus supplement. Institutions with whom the contracts, when authorized, may
be made include commercial and savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions,
and other institutions, but shall in all cases be subject to our approval. Delayed delivery contracts will be subject only to those conditions
set forth in the prospectus supplement, and the prospectus supplement will set forth any commissions we pay for solicitation of these
contracts.
Agents,
underwriters and other third parties described above may be entitled to indemnification by us against certain civil liabilities, including
liabilities under the Securities Act of 1933, or to contribution with respect to payments which the agents or underwriters may be required
to make in respect thereof. Agents, underwriters and such other third parties may be customers of, engage in transactions with, or perform
services for us in the ordinary course of business.
One
or more firms, referred to as “remarketing firms,” may also offer or sell the securities, if the prospectus supplement so
indicates, in connection with a remarketing arrangement upon their purchase. Remarketing firms will act as principals for their own accounts
or as our agents. These remarketing firms will offer or sell the securities in accordance with the terms of the securities. The prospectus
supplement will identify any remarketing firm and the terms of its agreement, if any, with us and will describe the remarketing firm’s
compensation. Remarketing firms may be deemed to be underwriters in connection with the securities they remarket. Remarketing firms may
be entitled under agreements that may be entered into with us to indemnification by us against certain civil liabilities, including liabilities
under the Securities Act of 1933, and may be customers of, engage in transactions with, or perform services for us in the ordinary course
of business.
Certain
of the underwriters may use this prospectus and the accompanying prospectus supplement for offers and sales related to market making
transactions in the securities. These underwriters may act as principal or agent in these transactions, and the sales will be made at
prices related to prevailing market prices at the time of sale.
The
securities may be new issues of securities and may have no established trading market. The securities may or may not be listed on a national
securities exchange. Underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market
making at any time without notice. We can make no assurance as to the liquidity of or the existence of trading markets for any of the
securities.
Certain
persons participating in this offering may engage in overallotment, stabilizing transactions, short covering transactions, and penalty
bids in accordance with rules and regulations under the Securities Exchange Act of 1934, or the Exchange Act. Overallotment involves
sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying
security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchase of the securities
in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling
concession from a dealer when the securities originally sold by the dealer are purchased in a covering transaction to cover short positions.
Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue
any of the activities at any time.
DESCRIPTION
OF OUR SHARE CAPITAL
The
concept of authorized share capital no longer exists in Australia and as a result, our authorized share capital is unlimited. All our
outstanding ordinary shares are validly issued, fully paid and non-assessable. The rights attached to our ordinary shares are as follows:
Dividend
rights. If our board of directors recommends a dividend, registered holders of our ordinary shares may declare a dividend by ordinary
resolution in a general meeting. The dividend, however, cannot exceed the amount recommended by our board of directors. Our board of
directors may declare an interim dividend. No dividend may be paid except out of our profits.
Voting
rights. Holders of ordinary shares have one vote for each ordinary share held on all matters submitted to a vote of shareholders.
Such voting rights may be affected by the grant of any special voting rights to the holders of a class of shares with preferential rights
that may be authorized in the future.
The
quorum required for an ordinary meeting of shareholders consists of at least two shareholders represented in person or by proxy who hold
or represent, in the aggregate, at least one third of the voting rights of the issued share capital. A meeting adjourned for lack of
a quorum generally is adjourned to the same day in the following week at the same time and place or any time and place as the directors
designate in a notice to the shareholders. At the reconvened meeting, the required quorum consists of any two members present in person
or by proxy.
An
ordinary resolution, such as a resolution for the declaration of dividends, requires approval by the holders of a majority of the voting
rights represented at the meeting, in person, by proxy or by written ballot and voting thereon. Under our Constitution, a special resolution,
such as amending our Constitution, approving any change in capitalization, winding-up, authorization of a class of shares with special
rights, or other changes as specified in our Constitution, requires approval of a special majority, representing the holders of no less
than 75% of the voting rights represented at the meeting in person, by proxy or by written ballot, and voting thereon.
Pursuant
to our Constitution, our directors are elected at our annual general meeting of shareholders by a vote of the holders of a majority of
the voting power represented and voting at such meeting.
Rights
in our profits. Our shareholders have the right to share in our profits distributed as a dividend and any other permitted distribution.
Rights
in the event of liquidation. In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be
distributed to the holders of ordinary shares in proportion to the nominal value of their holdings. This right may be affected by the
grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized
in the future.
Changing
Rights Attached to Shares
According
to our Constitution, in order to change the rights attached to any class of shares, unless otherwise provided by the terms of the class,
such change must be adopted by a general meeting of the shareholders and by a separate general meeting of the holders of the affected
class with a majority of 75% of the voting power participating in such meeting.
Annual
and Extraordinary Meetings
Our
Board of Directors must convene an annual meeting of shareholders at least once every calendar year, within five months of our last fiscal
year-end balance sheet data. Notice of at least twenty-eight (28) days prior to the date of the meeting is required. An extraordinary
meeting may be convened by the board of directors, if it decides or upon a demand of any directors, or of one or more shareholders holding
in the aggregate at least five percent (5%) of our issued capital. An extraordinary meeting must be called not more than twenty-one (21)
days after the request is made. The meeting must be held not later than two months after requested.
Limitations
on the Rights to Own Securities in Our Company
Neither
our Constitution nor the laws of the Commonwealth of Australia restrict in any way the ownership or voting of our shares.
Changes
in Our Capital
Pursuant
to the Listing Rules of the Australian Securities Exchange, our directors may in their discretion issue securities equal to not more
than 25% of our issued capital within a 12-month period. Issuances of securities in excess of such amount require the approval of our
shareholders by an ordinary resolution, unless made under an exception contained in the Listing Rules of the Australian Securities Exchange
which includes, among other things, a pro rata offer to shareholders, offers or issues made under previously approved employee incentive
schemes and share purchase plans under Australian law involving an offer of up to A$30,000 of shares at the applicable price.
DESCRIPTION
OF OUR AMERICAN DEPOSITARY SHARES
American
Depositary Shares
The
Bank of New York Mellon, as depositary, will register and deliver ADSs. Each ADS represents six hundred ordinary shares (or a right to
receive six hundred ordinary shares) deposited with HSBC Custody Nominees (Australia) Limited, as custodian for the depositary. Each
ADS also represents any other securities, cash or other property which may be held by the depositary. The depositary’s corporate
trust office at which the ADSs are administered is located at 101 Barclay Street, New York, New York 10286. The Bank of New York
Mellon’s principal executive office is located at 240 Greenwich Street, New York, New York 10286.
You
may hold ADSs either (A) directly (i) by having an American depositary receipt, which is a certificate evidencing a specific
number of ADSs, registered in your name, or (ii) by holding ADSs in the Direct Registration System, or (B) indirectly through
your broker or other financial institution. If you hold ADSs directly, you are an ADS holder. This description assumes you hold your
ADSs directly. If you hold the ADSs indirectly, you must rely on the procedures of your broker or other financial institution to assert
the rights of ADR holders described in this section. You should consult with your broker or financial institution to find out what those
procedures are.
The
Direct Registration System is a system administered by DTC pursuant to which the depositary may register the ownership of uncertificated
ADSs, which ownership shall be confirmed by periodic statements issued by the depositary to the ADS holders entitled thereto.
As
an ADS holder, we will not treat you as one of our shareholders and you will not have shareholder rights. Australian law governs shareholder
rights. The depositary will be the holder of the shares underlying your ADSs. As a holder of ADSs, you will have ADS holder rights. A
deposit agreement among us, the depositary and you, as an ADS holder, and the beneficial owners of ADSs set out ADS holder rights as
well as the rights and obligations of the depositary. New York law governs the deposit agreement and the ADSs.
The
following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire
deposit agreement and the form of American depositary receipt. Directions on how to obtain copies of those documents are provided under
“Where You Can Find Additional Information.”
Dividends
and Other Distributions
If
We Pay a Dividend or Other Distribution, How Will You Receive Dividends and Other Distributions on the Shares?
In
the event that we pay a cash dividend or make another distribution, the depositary has agreed to pay to you the cash dividends or other
distributions it or the custodian receives on shares or other deposited securities, after deducting its fees and expenses. You will receive
these distributions in proportion to the number of shares your ADSs represent.
| ● | Cash. The
depositary will convert any cash dividend or other cash distribution we pay on the shares into U.S. dollars, if it can do so on
a reasonable basis and can transfer the U.S. dollars to the United States. If that is not possible or if any government approval
is needed and cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency only to those ADR holders
to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of the ADS holders who have not
been paid. It will not invest the foreign currency and it will not be liable for any interest. |
Before
making a distribution, any withholding taxes, or other governmental charges that must be paid will be deducted. The depositary will distribute
only whole U.S. dollars and cents and will round fractional cents to the nearest whole cent. If exchange rates fluctuate during
a time when the depositary cannot convert the foreign currency, you may lose some or all of the value of the distribution.
|
● |
Shares. The
depositary may distribute additional ADSs representing any shares we distribute as a dividend or free distribution. The depositary
will only distribute whole ADSs. It will sell shares which would require it to deliver a fractional ADS and distribute the net proceeds
in the same way as it does with cash. If the depositary does not distribute additional ADSs, the outstanding ADSs will also represent
the new shares. |
|
● |
Rights
to Purchase Additional Shares. If we offer holders of our securities any rights to subscribe for additional shares or any
other rights, the depositary may make these rights available to you. If the depositary decides it is not legal and practical to make
the rights available but that it is practical to sell the rights, the depositary will use reasonable efforts to sell the rights and
distribute the proceeds in the same way as it does with cash. The depositary will allow rights that are not distributed or sold to
lapse. In that case, you will receive no value for them. |
If
the depositary makes rights available to you, it will exercise the rights and purchase the shares on your behalf. The depositary will
then deposit the shares and deliver ADSs to you. It will only exercise rights if you pay it the exercise price and any other charges
the rights require you to pay.
U.S. securities
laws may restrict transfers and cancellation of the ADSs represented by shares purchased upon exercise of rights. For example, you may
not be able to trade these ADSs freely in the United States. In this case, the depositary may deliver restricted depositary shares that
have the same terms as the ADSs described in this section except for changes needed to put the necessary restrictions in place.
|
● |
Other
Distributions. The depositary will send to you anything else we distribute on deposited securities by any means
it thinks is legal, fair and practical. If it cannot make the distribution in that way, the depositary has a choice. It may decide
to sell what we distributed and distribute the net proceeds, in the same way as it does with cash. Or, it may decide to hold what
we distributed, in which case ADSs will also represent the newly distributed property. However, the depositary is not required to
distribute any securities (other than ADSs) to you unless it receives satisfactory evidence from us that it is legal to make that
distribution. |
The
depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. We
have no obligation to register ADSs, shares, rights or other securities under the Securities Act. We also have no obligation to take
any other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. This means that you may
not receive the distributions we make on our shares or any value for them if it is illegal or impractical for us to make them available
to you.
Deposit,
Withdrawal and Cancellation
How
Are ADSs Issued?
The
depositary will deliver ADSs if you or your broker deposits shares or evidence of rights to receive shares with the custodian. Upon payment
of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will register
the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon the order of the person or persons entitled
thereto.
How
Do ADS Holders Cancel an ADS?
You
may turn in your ADSs at the depositary’s corporate trust office. Upon payment of its fees and expenses and of any taxes or charges,
such as stamp taxes or stock transfer taxes or fees, the depositary will deliver the shares and any other deposited securities underlying
the ADSs to you or a person you designate at the office of the custodian. Or, at your request, risk and expense, the depositary will
deliver the deposited securities at its corporate trust office, if feasible.
How
Do ADS Holders Interchange Between Certificated ADSs and Uncertificated ADSs?
You
may surrender your ADR to the depositary for the purpose of exchanging your ADR for uncertificated ADSs. The depositary will cancel that
ADR and will send you a statement confirming that you are the owner of uncertificated ADSs. Alternatively, upon receipt by the depositary
of a proper instruction from a holder of uncertificated ADSs requesting the exchange of uncertificated ADSs for certificated ADSs, the
depositary will execute and deliver to you an ADR evidencing those ADSs.
Voting
Rights
How
Do You Vote?
You
may instruct the depositary to vote the deposited securities, but only if we ask the depositary to ask for your instructions. Otherwise,
you won’t be able to exercise your right to vote unless you withdraw the shares. However, you may not know about the meeting enough
in advance to withdraw the shares.
If
we ask for your instructions, the depositary will notify you of the upcoming vote and arrange to deliver our voting materials to you.
The materials will (1) describe the matters to be voted on and (2) explain how you may instruct the depositary to vote the
shares or other deposited securities underlying your ADSs as you direct. For instructions to be valid, the depositary must receive them
on or before the date specified. The depositary will try, as far as practical, subject to the laws of Australia and our Constitution,
to vote or to have its agents vote the shares or other deposited securities as you instruct. The depositary will only vote or attempt
to vote as you instruct.
We
cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your shares.
In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying
out voting instructions. This means that you may not be able to exercise your right to vote and there may be nothing you can do if
your shares are not voted as you requested.
In
order to give you a reasonable opportunity to instruct the depositary as to the exercise of voting rights relating to deposited securities,
if we request the depositary to act, we will try to give the depositary notice of any such meeting and details concerning the matters
to be voted upon sufficiently in advance of the meeting date.
Fees
and Expenses
Persons
Depositing or Withdrawing Shares Must Pay: |
|
For: |
● US$3.00
(or less) per 100 ADSs (or portion of 100 ADSs) |
|
● Issuance
of ADSs, including issuances resulting from a distribution of shares or rights or other property
● Cancellation
of ADSs for the purpose of withdrawal, including if the deposit agreement terminates |
|
|
|
● US$0.03
(or less) per ADS |
|
● Any
cash distribution to you |
|
|
|
● A
fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited
for issuance of ADSs |
|
● Distribution
of securities distributed to holders of deposited securities which are distributed by the depositary to ADS holders |
|
|
|
● US$1.50
(or less) per ADR |
|
● Transfers,
combination and split-up of ADRs |
|
|
|
● Expenses
of the depositary |
|
● Cable,
telex and facsimile transmissions (when expressly provided in the deposit agreement)
● Converting
foreign currency to U.S. dollars |
|
|
|
● Taxes
and other governmental charges the depositary or the custodian have to pay on any ADS or share underlying an ADS, for example,
stock transfer taxes, stamp duty or withholding taxes |
|
● As
necessary |
|
|
|
● Any
charges incurred by the depositary or its agents for servicing the deposited securities |
|
● As
necessary |
The
Bank of New York Mellon, as depositary, has agreed to reimburse us for expenses we incur that are related to establishment and maintenance
of the ADR program, including investor relations expenses and Nasdaq application and listing fees. There are limits on the amount of
expenses for which the depositary will reimburse us, but the amount of reimbursement available to us is not related to the amount of
fees the depositary collects from investors.
The
depositary collects its fees for issuance and cancellation of ADSs directly from investors depositing shares or surrendering ADSs for
the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors
by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary
may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging
the book-entry system accounts of participants acting for them. The depositary may generally refuse to provide fee-attracting services
until its fees for those services are paid.
Payment
of Taxes
You
will be responsible for any taxes or other governmental charges payable on your ADSs or on the deposited securities represented by any
of your ADSs. The depositary may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented
by your ADSs until such taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by
your ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will,
if appropriate, reduce the number of ADSs to reflect the sale and pay to you any proceeds, or send to you any property, remaining after
it has paid the taxes.
Reclassifications,
Recapitalizations and Mergers
If
we: |
|
Then: |
● Change
the nominal or par value of our shares
● Reclassify,
split up or consolidate any of the deposited securities
● Recapitalize,
reorganize, merge, liquidate, sell all or substantially all of our assets, or take any similar action |
|
● The
securities received by the depositary will become deposited securities. Each ADS will automatically
represent its equal share of the new deposited securities
● The
depositary may, and will if we ask it to, deliver new ADRs or ask you to surrender your outstanding ADRs in exchange for new ADRs
identifying the new deposited securities. |
Amendment
and Termination
How
May the Deposit Agreement Be Amended?
We
may agree with the depositary to amend the deposit agreement and the ADSs without your consent for any reason. If an amendment adds or
increases fees or charges, except for taxes and other governmental charges or expenses of the depositary for registration fees, facsimile
costs, delivery charges or similar items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding
ADSs until 30 days after the depositary notifies ADS holders of the amendment. At the time an amendment becomes effective, you
are considered, by continuing to hold your ADS, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended.
How
May the Deposit Agreement Be Terminated?
The
depositary will terminate the deposit agreement at our direction by mailing a notice of termination to the ADS holders then outstanding
at least 90 days prior to the date fixed in such notice for such termination. The depositary may also terminate the deposit agreement
by mailing a notice of termination to us and the ADS holders then outstanding if at any time 90 days shall have expired after the
depositary shall have delivered to our company a written notice of its election to resign and a successor depositary shall not have been
appointed and accepted its appointment.
After
termination, the depositary and its agents will do the following under the deposit agreement but nothing else: collect dividends and
other distributions on the deposited securities, sell rights and other property, and deliver shares and other deposited securities upon
cancellation of ADSs. One year after termination, the depositary may sell any remaining deposited securities by public or private sale.
After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement
for the pro rata benefit of the ADS holders that have not surrendered their ADSs. It will not invest the money and has no liability
for interest. The depositary’s only obligations will be to account for the money and other cash. After termination our only obligations
will be to indemnify the depositary and to pay fees and expenses of the depositary that we agreed to pay.
Limitations
on Obligations and Liability
Limits
on Our Obligations and the Obligations of the Depositary; Limits on Liability to Holders of ADSs
The
deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the liability
of the depositary. We and the depositary:
| ● | are
only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith; |
| ● | are
not liable if either of us is prevented or delayed by law or circumstances beyond our control from performing our obligations under the
deposit agreement; |
| ● | are
not liable if either of us exercises discretion permitted under the deposit agreement; |
| ● | have
no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf
of any other party if it involves expenses or liability unless you furnish satisfactory indemnity; |
| ● | may
rely upon the advice of or information from legal counsel, accountants, any person presenting shares for deposit and any other holder
of ADSs or any other person if we believe in good faith such person is competent to give such advice or information. |
In
the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances.
Requirements
for Depositary Actions
Before
the depositary will deliver or register a transfer of an ADS, make a distribution on an ADS, or permit withdrawal of shares, the depositary
may require:
| ● | payment
of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer
of any shares or other deposited securities; |
| ● | satisfactory
proof of the identity and genuineness of any signature or other information it deems necessary; and |
| ● | compliance
with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents. |
The
depositary may refuse to deliver ADSs or register transfers of ADSs generally when the transfer books of the depositary or our transfer
books are closed or at any time if the depositary or we think it advisable to do so.
Your
Right to Receive the Shares Underlying Your ADRs
You
have the right to cancel your ADSs and withdraw the underlying shares at any time except:
| ● | When
temporary delays arise because: (i) the depositary has closed its transfer books or we have closed our transfer books; (ii) the
transfer of shares is blocked to permit voting at a shareholders’ meeting; or (iii) we are paying a dividend on our shares. |
| ● | When
you or other ADS holders seeking to withdraw shares owe money to pay fees, taxes and similar charges. |
| ● | When
it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal
of shares or other deposited securities. |
This
right of withdrawal may not be limited by any other provision of the deposit agreement.
Pre-Release
of ADSs
The
deposit agreement permits the depositary to deliver ADSs before deposit of the underlying shares. This is called a pre-release of the
ADSs. The depositary may also deliver shares upon cancellation of pre-released ADSs (even if the ADSs are cancelled before the pre-release
transaction has been closed out). A pre-release is closed out as soon as the underlying shares are delivered to the depositary. The depositary
may receive ADSs instead of shares to close out a pre-release. The depositary may pre-release ADSs only under the following conditions:
(1) before or at the time of the pre-release, the person to whom the pre-release is being made represents to the depositary in writing
that it or its customer owns the shares or ADSs to be deposited and assigns all beneficial rights, title and interest in such shares
or ADSs to the depositary; (2) the pre-release is fully collateralized with cash or other collateral that the depositary considers
appropriate; and (3) the depositary must be able to close out the pre-release on not more than five business days’ notice.
In addition, the depositary will limit the number of ADSs that may be outstanding at any time as a result of pre-release to 30% of the
deposited shares, although the depositary may disregard the limit from time to time, if it thinks it is appropriate to do so.
DESCRIPTION
OF WARRANTS
We
may issue warrants to purchase ordinary shares represented by ADSs in one or more series together with other securities or separately,
as described in the applicable prospectus supplement. Below is a description of certain general terms and provisions of the warrants
that we may offer. Particular terms of the warrants will be described in the warrant agreements and the prospectus supplement for the
warrants.
The
applicable prospectus supplement will contain, where applicable, the following terms of and other information relating to the warrants:
| ● | the
specific designation and aggregate number of, and the price at which we will issue, the warrants; |
| ● | the
currency or currency units in which the offering price, if any, and the exercise price are payable; |
| ● | the
designation, amount, and terms of the securities purchasable upon exercise of the warrants; |
| ● | if
applicable, the exercise price for ordinary shares and the number of ordinary shares to be received upon exercise of the warrants; |
| ● | the
date on which the right to exercise the warrants will begin and the date on which that right will expire or, if you may not continuously
exercise the warrants throughout that period, the specific date or dates on which you may exercise the warrants; |
| ● | whether
the warrants will be issued in fully registered form or bearer form, in definitive or global form, or in any combination of these forms,
although, in any case, the form of a warrant included in a unit will correspond to the form of the unit and of any security included
in that unit; |
| ● | any
applicable material U.S. federal or Australian income tax consequences; |
| ● | the
identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents, transfer agents, registrars,
or other agents; |
| ● | the
proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any securities exchange; |
| ● | if
applicable, the date from and after which the warrants and the ordinary shares will be separately transferable; |
| ● | if
applicable, the minimum or maximum amount of the warrants that may be exercised at any other time; |
| ● | information
with respect to book-entry procedures, if any; |
| ● | the
anti-dilution provisions of the warrants, if any; |
| ● | any
redemption or call provisions; |
|
● |
whether
the warrants are to be sold separately or with other securities as parts of units; and |
| ● | any
additional terms of the warrants, including terms, procedures, and limitations relating to the exchange and exercise of the warrants. |
DESCRIPTION
OF UNITS
We
may, from time to time, issue units comprised of one or more of the other securities that may be offered under this prospectus, in any
combination.
Each
unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit
will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide
that the securities included in the unit may not be held or transferred separately at any time, or at any time before a specified date.
Any
applicable prospectus supplement will describe:
|
● |
the
material terms of the units and of the securities comprising the units, including whether and under what circumstances those securities
may be held or transferred separately; |
|
● |
any
material provisions relating to the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising
the units; and |
|
● |
any
material provisions of the governing unit agreement that differ from those described above. |
The
description in the applicable prospectus supplement of any units we offer will not necessarily be complete and will be qualified in its
entirety by reference to the applicable unit agreement, which will be filed with the SEC if we offer units. For more information on how
you can obtain copies of the applicable unit agreement if we offer units, see the sections entitled “Where You Can Find More Information”
and “Incorporation of Certain Information by Reference.” We urge you to read the applicable unit agreement and any applicable
prospectus supplement in their entirety.
FOREIGN
EXCHANGE CONTROLS AND OTHER LIMITATIONS
Australia
has largely abolished exchange controls on investment transactions. The Australian dollar is freely convertible into U.S. dollars. In
addition, there are currently no specific rules or limitations regarding the export from Australia of profits, dividends, capital, or
similar funds belonging to foreign investors, except that certain payments to non-residents must be reported to the Australian Cash Transaction
Reports Agency, which monitors such transactions, and amounts on account of potential Australian tax liabilities may be required to be
withheld unless a relevant taxation treaty can be shown to apply.
The
Foreign Acquisitions and Takeovers Act 1975
Under
Australian law, in certain circumstances foreign persons are prohibited from acquiring more than a limited percentage of the shares in
an Australian company without approval from the Australian Treasurer. These limitations are set forth in the Australian Foreign Acquisitions
and Takeovers Act, or the Takeovers Act.
An
acquisition of an interest in 10% or more of our issued voting shares by a foreign government investor (unless a country specific exception
applies) requires notification to and approval by the Australian Treasurer (usually through the Foreign Investments Review Board (“FIRB”)).
Under
the Takeovers Actany private foreign person (that is, a person who is not a foreign government investor), together with associates, is
prohibited from acquiring 20% or more of the shares in any company having total assets of A$310 million or more without notification
to and approval by the Australian Treasurer. However for investors from the U.S. and certain other countries, a threshold of A$1,339
million applies (except in certain circumstances).
If
the necessary approval is not obtained, the Treasurer may make an order requiring the acquirer to dispose of the shares it has acquired
within a specified period of time. At present, we do not have total assets of A$310 million.
The
notification and approval requirements may also apply to increases in interests above these levels (including passive increases without
an acquisition).
If
the necessary approvals are not obtained, the Treasurer may make an order requiring the acquirer to dispose of the shares it has acquired
within a specified period of time.
If
the level of foreign ownership exceeds 40% at any time, we would be considered a foreign person under the Takeovers Act. In such event,
we would be required to obtain the approval of the Treasurer for our company, together with our associates, to acquire (i) more than
20% of an Australian company or business of an Australian company or business with assets totaling over A$310 million; or (ii) any direct
or indirect ownership interest in Australian land or an agribusiness.
The
percentage of foreign ownership in our company would also be included in determining the foreign ownership of any Australian company
or business in which it may choose to invest. Since we have no current plans for any such acquisitions and do not own any property, any
such approvals required to be obtained by us as a foreign person under the Takeovers Act will not affect our current or future ownership
or lease of property in Australia.
Our
Constitution does not contain any additional limitations on a non-resident’s right to hold or vote our securities.
Australian
law requires the transfer of shares in our company to be made in writing. No stamp duty will be payable in Australia on the transfer
of ADSs.
TAXATION
If
required, the material Australian and U.S. federal income tax consequences relating to the purchase, ownership and disposition of any
of the securities offered by this prospectus will be set forth in the prospectus supplement offering those securities.
AUTHORIZED
REPRESENTATIVE
Our
authorized representative in the United States for this offering as required pursuant to Section 6(a) of the Securities Act of 1933,
is Puglisi & Associates; 850 Library Avenue, Suite 204; P.O. Box 885; Newark, Delaware 19715. We have agreed to indemnify the authorized
representative against liabilities under the Securities Act of 1933.
OFFERING
EXPENSES
The
following is a statement of expenses in connection with the distribution of the securities registered. All amounts shown are estimates
except the SEC registration fee. The estimates do not include expenses related to offerings of particular securities. Each prospectus
supplement describing an offering of securities will reflect the estimated expenses related to the offering of securities under that
prospectus supplement.
SEC registration fee | |
| TBA | |
FINRA fee | |
| TBA | |
EDGAR and printing fees | |
| 1,000 | |
Legal fees and expenses | |
| 10,000 | |
Accounting fees and expenses | |
| 20,000 | |
Depositary fees and
expenses | |
| 4,000 | |
Miscellaneous | |
| 2,000 | |
Total | |
US$ | | |
LEGAL
MATTERS
The
validity of the securities offered hereunder will be passed upon for us by QR Lawyers Pty Ltd., Melbourne, Australia, our Australian
counsel. Carter Ledyard & Milburn LLP, New York, New York, will be passing upon matters of United States law for us with respect
to securities offered by this prospectus and any accompanying prospectus supplement.
EXPERTS
The
financial statements incorporated in this pospectus by reference to the Annual Report on Form 20-F for the year ended June 30, 2023 have
been so incorporated in reliance on the report (which contains an explanatory paragraph relating to the Company's ability to continue
as a going concern as described in Note 1 to the financial statements) of PricewaterhouseCoopers, an independent registered public accounting
firm, given on the authority of said firm as experts in auditing and accounting.
WHERE
YOU CAN FIND MORE INFORMATION
We
filed a registration statement on Form F-3 to register with the SEC the securities described in this prospectus. This prospectus is part
of that registration statement. This prospectus, which constitutes a part of the registration statement, summarizes material provisions
of contracts and other documents that we refer to in the prospectus. Since this prospectus does not contain all of the information contained
in the registration statement, you should read the registration statement and its exhibits and schedules for further information with
respect to us and our ordinary shares and the ADSs. Our SEC filings, including the registration statement, are also available to you
on the SEC’s Web site at http://www.sec.gov.
We
are subject to the information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those
requirements we file reports with the SEC. As a foreign private issuer, we are exempt from the rules under the Exchange Act related to
the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting
and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the
Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as United
States companies whose securities are registered under the Exchange Act. However, we file with the SEC, within four months after the
end of each fiscal year, or such applicable time as required by the SEC, an annual report on Form 20-F containing financial statements
audited by an independent registered public accounting firm, and submit to the SEC, on Form 6-K, unaudited quarterly financial information
for the first three quarters of each fiscal year within 60 days after the end of each such quarter, or such applicable time as required
by the SEC.
INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE
The
SEC allows us to “incorporate by reference” information into this prospectus, which means that we can disclose important
information to you by referring you to other documents which we have filed or will file with the SEC. We are incorporating by reference
in this prospectus the documents listed below and all amendments or supplements we may file to such documents, as well as any future
filings we may make with the SEC on Form 20-F under the Exchange Act before the time that all of the securities offered by this prospectus
have been sold or de-registered.
|
● |
Our
Annual Report on Form 20-F for the fiscal year ended June 30, 2023, as filed with the Commission on August 31, 2023; |
|
● |
The
description of our ADRs contained in our Form
20-F for the fiscal year ended June 30, 2023. |
In
addition, we may incorporate by reference into this prospectus our reports on Form 6-K filed after the date of this prospectus (and before
the time that all of the securities offered by this prospectus have been sold or de-registered) if we identify in the report that it
is being incorporated by reference in this prospectus.
Certain
statements in and portions of this prospectus update and replace information in the above listed documents incorporated by reference.
Likewise, statements in or portions of a future document incorporated by reference in this prospectus may update and replace statements
in and portions of this prospectus or the above listed documents.
We
will provide you without charge, upon your written or oral request, a copy of any of the documents incorporated by reference in this
prospectus, other than exhibits to such documents which are not specifically incorporated by reference into such documents. Please direct
your written or telephone requests to:
Alterity
Therapeutics Limited
Level
14, 350 Collins Street
Melbourne,
Victoria 3000 Australia
Attn.:
Kathryn Andrews, Chief Financial Officer
Telephone
number +61-3-9349-4906.
You
may also obtain information about us by visiting our website at http://www.alteritytherapeutics.com. Information contained in our website
is not part of this prospectus.
We
are an Australian company and are a “foreign private issuer” as defined in Rule 3b-4 under the Exchange Act. As a result,
(1) our proxy solicitations are not subject to the disclosure and procedural requirements of Regulation 14A under the Exchange Act, (2)
transactions in our equity securities by our officers and directors are exempt from Section 16 of the Exchange Act, and (3) we are not
required under the Exchange Act to file periodic reports and financial statements as frequently or as promptly as U.S. companies whose
securities are registered under the Exchange Act. We make all required filings with the SEC electronically, and these filings are available
over the Internet at the SEC’s website at http://www.sec.gov.
ENFORCEABILITY
OF CIVIL LIABILITIES
Service
of process upon us and upon our directors and officers and the Australian experts named in this prospectus, most of whom reside outside
the United States, may be difficult to obtain within the United States. Furthermore, because substantially all of our assets and substantially
all of our directors and officers are located outside the United States, any judgment obtained in the United States against us or any
of such directors and officers may not be collectible within the United States.
We
have irrevocably appointed Puglisi & Associates as our agent to receive service of process in any action against us in the state
and federal courts sitting in the City of New York, Borough of Manhattan arising out of this offering or any purchase or sale of securities
in connection therewith. We have not given consent for this agent to accept service of process in connection with any other claim.
ALTERITY
THERAPEUTICS LIMITED
Ordinary
Shares represented by American Depositary Shares
Warrants
Units
PROSPECTUS
You
should rely only on the information incorporated by reference or provided in this prospectus and in any accompanying prospectus supplement.
We have not authorized anyone to provide you with different information. We are not making any offer to sell or buy any of the securities
in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date
other than the date that appears below.
2023
PART
II
INFORMATION
NOT REQUIRED IN PROSPECTUS
Item
8. Indemnification of Directors and Officers.
Our
Constitution provides that, subject to the Australian Corporations Act, every director, secretary, manager or officer of our company
or any person employed by our company as auditor shall be indemnified out of our funds against all liability incurred by such person
as a director or officer in defending proceedings, whether civil or criminal, in which judgment is given in the persons favor or in which
the person is acquitted in connection with any application under the Australian Corporations Act in which relief is granted to the person
by a Court.
Under
our Constitution no director, auditor or other officer shall be liable for (i) any acts, receipts, neglect or defaults of any other director
or officer for joining in any receipt or other act for conformity; (ii) any loss or expense that may happen to us through the inefficiency
or deficiency of title to any property acquired by order of the directors or on our behalf; (iii) the inefficiency or deficiency of any
security in or upon which any of our monies shall be invested; (iv) any loss or damage arising from bankruptcy, insolvency or tortuous
act of any person with whom any monies, securities or effects shall be deposited; (v) any loss occasioned by any error of judgment, omission,
default or oversight on the persons part; or (vi) any other loss damage or misfortune whatsoever which shall happen in relation to those
things unless the same shall happen through the persons own negligence, default, breach or duty, breach of trust or dishonesty.
In
addition, our Constitution provides that to the extent permitted by law, we may pay, or agree to pay, a premium in respect of a contract
insuring a person who is liable or has been an officer of our company or one of our subsidiaries against a liability:
| ● | incurred
by the person in his or her capacity as an officer of our company or a subsidiary of our company provided that the liability does not
arise out of a conduct involving a willful breach of duty in relation to our company or a subsidiary of our company; or |
|
● |
for
costs and expenses incurred by that person defending proceedings, whatever their outcome. |
We
maintain a directors’ and officers’ liability insurance policy. We have established a policy for the indemnification of our
directors and officers against certain liabilities incurred as a director or officer, including costs and expenses associated in successfully
defending legal proceedings.
Item
9. Exhibits.
The
index to exhibits appears below on the page immediately following the signature pages of this Registration Statement.
Item
10. Undertakings.
(1)
The undersigned registrant hereby undertakes:
| (a) | to
file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement: |
| (i) | to
include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, or the Securities Act; |
| (ii) | to
reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration
Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate,
the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the ‘‘Calculation
of Registration Fee’’ table in the effective registration statement; and |
| (iii) | to
include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any
material change to such information in this Registration Statement; |
provided,
however, that paragraphs (i), (ii) and (iii) above do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in periodic reports filed with or furnished to the Securities and Exchange Commission by the
registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934, or the Exchange Act, that are incorporated
by reference in this Registration Statement or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the
Registration Statement.
| (b) | that,
for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
be the initial bona fide offering thereof. |
| (c) | to
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering. |
| (d) | To
file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A. of Form 20-F
at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by
Section 10(a)(3) of the Securities Act need not be furnished, provided that the registrant includes in the prospectus, by means
of a post-effective amendment, financial statements required pursuant to this paragraph and other information necessary to ensure that
all other information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing,
a post-effective amendment need not be filed to include financial statements and information required by Section 10(a)(3) of the Securities
Act or Rule 3-19 of Regulation S-K if such financial statements and information are contained in periodic reports filed with or furnished
to the Securities and Exchange Commission by the registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated
by reference in the Form F-3. |
| (e) | that,
for the purpose of determining any liability under the Securities Act to any purchaser: |
| (i) | each
prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be a part of the registration statement as of the
date the filed prospectus was deemed part of and included in the registration statement; and |
| (ii) | each
prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on
Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the
information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement
as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of
securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person
that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the
securities in the registration statement to which the prospectus relates, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof; provided, however, that no statement made in a registration statement or prospectus
that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration
statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such
effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration
statement or made in any such document immediately prior to such effective date. |
| (f) | that,
for the purpose of determining liability of a registrant under the Securities Act to any purchaser in the initial distribution of the
securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to
this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are
offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the
purchaser and will be considered to offer or sell such securities to such purchaser: |
| (i) | any
preliminary prospectus or prospectus of the undersigned registrant to the offering required to be filed pursuant to Rule 424; |
| (ii) | any
free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by an
undersigned registrant; |
| (iii) | the
portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and |
| (iv) | any
other communication that is an offer in the offering made by the undersigned registrant to the purchaser. |
(2)
The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of
the registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each
filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference
in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the
offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3)
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons
of the registrant pursuant to the provisions referred to in Item 15, or otherwise, the registrant has been advised that in the opinion
of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses
incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will,
unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the
final adjudication of such issue.
(4)
The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, the information
omitted from the form of prospectus filed as part of this Registration Statement in reliance upon Rule 430A and contained in a form
of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed
to be part of this Registration Statement as of the time it was declared effective.
(5)
The undersigned registrant hereby undertakes that, for the purpose of determining any liability under the Securities Act, each post-effective
amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein,
and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
SIGNATURES
Pursuant
to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it complies with all
of the requirements for filing on Form F-3 and has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in Melbourne, Australia, on
September
29, 2023.
|
By: |
/s/
David A. Stamler |
|
|
David
A. Stamler |
|
|
Chief
Executive Officer |
KNOW
ALL PERSONS BY THESE PRESENTS, each director and officer whose signature appears below constitutes and appoints, David A. Stamler and
Kathryn Andrews or either of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution,
to sign in any and all capacities any and all amendments or post-effective amendments to this registration statement on Form F-3, and
to sign any and all additional registration statements relating to the same offering of securities of the Registration Statement that
are filed pursuant to Rule 462(b) of the Securities Act, and to file the same with all exhibits thereto and other documents in connection
therewith with the Securities and Exchange Commission, granting such attorney-in-fact and agent full power and authority to do all such
other acts and execute all such other documents as he or she may deem necessary or desirable in connection with the foregoing, as fully
as the undersigned may or could do in person, hereby ratifying and confirming all that such attorney-in-fact and agent may lawfully do
or cause to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act, this registration statement has been signed below by the following persons in the capacities
indicated on September 29, 2023.
Signature |
|
Title |
|
|
|
/s/
David A. Stamler |
|
Chief Executive Officer |
David
A. Stamler |
|
|
|
|
|
/s/
Kathryn J. E. Andrews |
|
Chief
Financial Officer |
Kathryn
J. E. Andrews |
|
|
|
|
|
/s/
Geoffrey P. Kempler |
|
Chairman
of the Board of Directors |
Geoffrey
P. Kempler |
|
|
|
|
|
/s/
Lawrence Gozlan |
|
Director |
Lawrence
Gozlan |
|
|
|
|
|
/s/
Peter Marks |
|
Director |
Peter
Marks |
|
|
|
|
|
/s/
Brian D. Meltzer |
|
Director |
Brian
D. Meltzer |
|
|
Puglisi
& Associates |
Authorized
Representative in the United States |
|
|
|
|
By:
|
/s/
Greg Lavelle |
|
|
Name:
|
Greg
Lavelle |
|
|
Title: |
Managing
Director |
|
| (1) | Incorporated
by reference, if necessary, to a corresponding exhibit to a Current Report on Form 6-K in connection with an offering of securities. |
| (2) | Incorporated
by reference to the Registrant’s Annual Report on Form 20-F for the year ended June 30, 2009 (File No. 000-49843). |
| (3) | Incorporated
by reference to the Form F-6 Registration Statement filed with the Securities and Exchange Commission on November 6, 2014 (File No. 333-199907). |
II-5
Exhibit 5.1
Our Ref: 013501-26
29 September 2023
Alterity Therapeutics Limited
Suite 4, Level 14, 350 Collins Street
MELBOURNE, VICTORIA 3000
Australia
Dear Sir and Madam,
|
RE: |
REGISTRATION STATEMENT ON FORM F-3 OF ALTERITY THERAPEUTICS LIMITED |
We are acting as Australian counsel to Alterity
Therapeutics Limited ACN 080 699 065, an Australian company (the “Company”) in connection with the filing with the Securities
and Exchange Commission (the “Commission”) of a Registration Statement on Form F-3 (the “Registration Statement”),
under the Securities Act of 1933, as amended. The Registration Statement relates to the registration of up to $50,000,000 aggregate amount
of the following securities of the Registrant: (i) American depositary shares (“ADSs”), with each ADS representing sixty ordinary
shares, no par value, of the Registrant (“the Ordinary Shares”), (ii) warrants to purchase Ordinary Shares represented by
ADSs (“the Warrants”) and (iii) units consisting of Warrants and Ordinary Shares (“the Units”), and together with
the ADSs and Warrants, “the Securities”).
We have examined the Registration Statement and
such corporate records, certificates and other documents, and such questions of law, as we have considered necessary or appropriate for
the purpose of our opinion. In our examination we have assumed with your permission and without independent verification:
|
(a) |
the genuineness of all signatures and the authenticity of all documents, instruments and certificates submitted to us as originals and the exact conformity with the authentic originals of all documents, instruments and certificates submitted to us as copies or forms or originals; |
|
(b) |
that each party to each document has all the requisite power and authority (corporate and otherwise) to execute and deliver and perform its obligations thereunder; |
|
(c) |
that any documents which purport to be governed by the law of any jurisdiction other than the law of Victoria, Australia are legal, valid and binding obligations on all of the parties thereto and under the applicable law and that none of the execution, delivery or performance of any document by any party thereto violates or contravenes or is rendered invalid, not binding or unenforceable under any applicable law under any jurisdiction other than the law of Victoria, Australia; |
|
(d) |
that each party to each document, other than the Registrant, is duly organized validly existing and in good standing under the laws of its jurisdiction of incorporation; and |
|
(e) |
that the execution and delivery by each party of each document and the performance by each party of its obligations under each document to which it is a party has been duly authorized by all necessary corporate and other actions. |
As to various questions of fact relevant to this
opinion, we have relied upon and assumed the accuracy of, without independent verification, certificates and oral or written statements
or the information of or from public officials, officers or representatives of the Registrant and others.
We have relied conclusively upon certified copies
of the Registrant’s Constitution, certificates of officers of the Registrant, the contents of the minute’s book and other
records of corporate proceedings of the Registrant, as to various factual matters. We have relied as to matters of fact, without independent
verification, upon certificates of officers of the Registrant.
This opinion which shall be governed by and construed
in accordance with the laws of Victoria, Australia, is given only with respect to Australian law that is in effect on the date of this
opinion. We have not investigated the laws of any jurisdiction other than Australia. We express no opinion as to tax law or international
law. We have assumed that any applicable law (other than Australian law) does not affect this opinion.
29 September 2023
We are qualified to practice law in Victoria,
Australia and do not express any opinions in this letter concerning any laws other than the laws of Australia to the extent necessary
to render the opinions set forth herein. We are not opining on, and we assume no responsibility as to the applicability to or effect on
any of the matters covered herein of the laws of any jurisdiction.
Upon the basis of such examination, we are of
the opinion that:
|
1. |
When the issuance of the Ordinary Shares has been duly authorized by appropriate corporate action, and the Ordinary Shares have been duly issued, sold and delivered in accordance with the applicable definitive purchase agreement or other similar agreement approved by, or on behalf of, the Registrant’s Board of Directors, the Ordinary Shares will be legally issued, fully paid and non-assessable. |
|
2. |
When the issuance of the Warrants has been duly authorized by appropriate corporate action, and the Warrants have been duly executed and delivered against payment therefore, pursuant to a warrant agreement or agreements duly authorized, executed and delivered by the Registrant and a warrant agent, the Warrants will be valid and binding obligations of the Registrant, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors’ rights and to general equity principles. |
|
a. |
When the issuance of the Ordinary Shares issuable upon the exercise of any Warrants has been duly authorized by appropriate corporate action, and the Ordinary Shares have been duly issued, and the Registrant has received any additional consideration which is payable upon the exercise of the Warrants, the Ordinary Shares will be legally issued, fully paid and non-assessable. |
|
3. |
When the issuance of the Units has been duly authorized by appropriate corporate action and the Units have been duly issued, sold and delivered pursuant to the Unit Agreement or similar agreement approved by, or on behalf of, the Board of Directors of the Registrant, the Units will be valid issued and will entitle the holders thereof to the rights specified in the Unit Agreement. |
This opinion speaks solely as of its date and
we undertake no obligation to advise you of any changes (including but not limited to any subsequently enacted, published or reported
laws, regulations or individual decisions) that may occur or come to our attention after the date hereof.
This opinion letter is furnished at your request
and is solely for your benefit and may not be used, circulated, quoted or referred to by you or by any other person or entity or for any
other purpose without our express prior written consent.
We hereby consent to the filing of this opinion as an exhibit to the
Registration Statement and to the references to our name under the headings “Legal Matters” and “Enforceability of Civil
Liabilities” in the Prospectus which is a part of the Registration Statement.
Yours faithfully
QR LAWYERS PTY LTD
/s/ DAVID RODDA
DAVID RODDA
PARTNER
d.rodda@qrlawyers.com.au
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM
We hereby consent to the incorporation by reference in this Registration
Statement on Form F-3 of Alterity Therapeutics Limited of our report dated August 31, 2023 relating to the financial statements, which
appears in Alterity Therapeutic Limited’s Annual Report on Form 20-F for the year ended June 30, 2023. We also consent to the reference
to us under the heading “Experts” in such Registration Statement.
/s/ PricewaterhouseCoopers
Melbourne, Australia
September 28, 2023
Exhibit 107
Calculation of Filing Fee Tables
Form F-3
(Form Type)
ALTERITY THERAPEUTICS
LIMITED.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward
Securities
| |
Security Type | |
Security Class Title | |
Fee Calculation or Carry Forward Rule | |
Amount Registered | | |
Proposed Maximum Offering Price Per
Unit | | |
Maximum Aggregate Offering Price (1) | | |
Fee Rate | | |
Amount of Registration Fee | |
Fees to Be Paid | |
Equity | |
Ordinary shares, no par value per share | |
| |
| | |
| | |
| | |
| | |
| |
| |
Other | |
Warrants | |
| |
| | |
| | |
| | |
| | |
| |
| |
Other | |
Units | |
| |
| | |
| | |
| | |
| | |
| |
| |
Unallocated (Universal) Shelf | |
Unallocated (Universal) Shelf | |
457(o) | |
| | (2) | |
| | (3) | |
$ | 50,000,000 | | |
| 0.0001102 | | |
$ | 5,510.00 | |
| |
| |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | |
| |
Total Offering Amounts | | |
| | | |
| | | |
| | | |
$ | 5,510.00 | |
| |
Total Fees Previously Paid | | |
| | | |
| | | |
| | | |
| - | |
| |
Total Fee Offsets | | |
| | | |
| | | |
| | | |
$ | 3,839 | |
| |
Net Fee Due | | |
| | | |
| | | |
| | | |
$ | 1671.00 | |
(1) |
The proposed maximum aggregate offering price per class of security will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security pursuant to instructions to Form F-3 under the Securities Act, as amended, or the Securities Act. |
(2) |
There are being registered hereunder such indeterminate number of the securities of each identified class being registered as may be sold by the registrant from time to time at indeterminate prices, with the maximum aggregate public offering price not to exceed $50,000,000. Also includes such indeterminate number of securities of the registrant as may be issued upon exercise, conversion or exchange of these securities. Separate consideration may or may not be received for securities that are issuable upon exercise, conversion or exchange of other securities. |
(3) |
The proposed maximum aggregate price per unit of each class of securities will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of securities pursuant to the General Instruction II.C. of Form F-3 under the Securities Act of 1933. |
Table 2: Fee Offset Claims and Sources
| |
Registrant or Filer Name | |
Form or Filing Type | |
File Number | |
Initial Filing Date | |
Filing Date | |
Fee Offset Claimed | | |
Security Type Associated with Fee Offset Claimed | |
Security Title Associated with Fee Offset Claimed | |
Unsold Securities Associated with Fee Offset Claimed | |
Unsold Aggregate Offering Amount Associated with Fee Offset Claimed | | |
Fee Paid with Fee Offset Source | |
Rule 457(p) |
Fee Offset Claims | |
ALTERITY THERAPEUTICS LIMITED | |
F-3 | |
333-249311 (4) | |
October 5,
2020 | |
N/A | |
$ | 1,212 | | |
Equity | |
Ordinary Shares | |
N/A | |
$ | 34,843,106 | | |
| N/A | |
Fee Offset Sources | |
ALTERITY THERAPEUTICS LIMITED | |
F-3 | |
333-249311 (4) | |
N/A | |
October 9,
2020 | |
| N/A | | |
N/A | |
N/A | |
N/A | |
| N/A | | |
$ | 3,839 | |
(4) |
Attributable to $34,843,106 of unsold securities ($3,839 of previously paid fees) that were previously registered under the Registration Statement on Form F-3 (333-249311) on October 9, 2020 (the “Prior Registration Statement”) that have not yet been issued and sold. Pursuant to Rule 457(p) under the Securities Act, such unutilized filing fees may be applied to the filing fees payable pursuant to this Registration Statement, and the Prior Registration Statement and the offering of the unsold securities registered under the Prior Registration Statement will be deemed terminated as of the effective date of this Registration Statement. |
Alterity Therapeutics (PK) (USOTC:PRNAF)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Alterity Therapeutics (PK) (USOTC:PRNAF)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024